论文部分内容阅读
目的观察雷贝拉唑联合泮托拉唑治疗消化性溃疡患者临床疗效及安全性,为消化性溃疡患者的治疗提供一定的参考。方法选取医院收治的消化性溃疡患者78例,随机分为观察组和对照组,每组38例。观察组采用雷贝拉唑联合泮托拉唑治疗,对照组采用奥美拉唑治疗,观察2组患者的治疗效果及不良反应发生情况。结果观察组治愈率和总有效率分别为61.54%、94.87%,均高于对照组的41.03%、82.05%(P<0.05);观察组不良反应发生率为5.13%,低于对照组的20.51%(P<0.05)。结论雷贝拉唑联合泮托拉唑治疗消化性溃疡起效快、疗效好、不良反应少,能较快缓解腹痛,值得临床推广应用。
Objective To observe the clinical efficacy and safety of rabeprazole combined with pantoprazole in the treatment of patients with peptic ulcer and provide some reference for the treatment of patients with peptic ulcer. Methods 78 patients with peptic ulcer admitted to the hospital were randomly divided into observation group and control group with 38 cases in each group. The observation group was treated with rabeprazole combined with pantoprazole, while the control group was treated with omeprazole. The therapeutic effect and adverse reactions of the two groups were observed. Results The cure rate and total effective rate in the observation group were 61.54% and 94.87%, respectively, which were higher than those in the control group (41.03% and 82.05%, P <0.05). The adverse reaction rate in the observation group was 5.13%, which was lower than that in the control group % (P <0.05). Conclusions Rabeprazole combined with pantoprazole is effective in treating peptic ulcer with good curative effect and less adverse reactions. It can relieve abdominal pain more quickly and is worthy of clinical application.